Cargando…

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib, and the progressive disease is often quite a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905592/ https://www.ncbi.nlm.nih.gov/pubmed/33627156 http://dx.doi.org/10.1186/s13045-021-01039-9

Ejemplares similares

Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells
por: Goswami, Ria, et al.
Publicado: (2021)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib
por: Nakhoda, Shazia, et al.
Publicado: (2023)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
por: Guinn, Daphne, et al.
Publicado: (2014)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
por: Timofeeva, Natalia, et al.
Publicado: (2021)

Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012)

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
por: Elgamal, Ola A., et al.
Publicado: (2020)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Davis, Joanne E., et al.
Publicado: (2021)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
por: Reda, Gianluigi, et al.
Publicado: (2018)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
por: Chowdhury, Subir Roy, et al.
Publicado: (2021)

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients
por: Diamond, Akiva, et al.
Publicado: (2023)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma
por: Choueiry, Fouad, et al.
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
por: Reda, Gianluigi, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Clinical course of COVID-19 in a patient with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) under ibrutinib therapy: a case report
por: Cecyn, Karin Zattar, et al.
Publicado: (2021)

Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease
por: Ahmed, Elshafa Hassan, et al.
Publicado: (2021)

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
por: Rendeiro, André F., et al.
Publicado: (2020)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
por: Broccoli, Alessandro, et al.
Publicado: (2021)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
por: Dartigeas, Caroline, et al.
Publicado: (2022)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Adding SNX to the mix: SNX9 drives filopodia biogenesis
por: Lebek, Nadine M., et al.
Publicado: (2020)

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
por: Rogers, Andrew, et al.
Publicado: (2020)

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
por: Eisenmann, Eric D., et al.
Publicado: (2021)

Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
por: Mahlich, Jörg, et al.
Publicado: (2017)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
por: Qerama, Shaqir, et al.
Publicado: (2023)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_50km8a58c6k9upl9l42mrfh5c7